ALX Oncology Holdings Inc
ALXO
ISIN US00166B1052 / Valor 55754366
ALX Oncology Holdings Inc
UMushroom community rating:
About company
ALX Oncology Holdings Inc is a clinical stage biotechnology company focused on developing innovative immuno-oncology therapies for cancer. The company's lead candidate, evorpacept, is designed to bind CD47 with greater affinity than natural SIRPα, aiming to block the "don't eat me" signal on cancer cells and activate the immune system to fight against cancer. ALX Oncology's strategy is to pursue evorpacept as a critical component for future combination treatments in oncology, leveraging the immune activation of widely used anti-cancer agents. With promising clinical results in multiple oncology indications, the company aims to address fundamental challenges in blocking CD47 and realize the full potential of this therapeutic target.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
181 M
Market cap (USD)
45,758
Daily traded volume (Shares)
2.26 / 2.145
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
